News
Calliditas reveals results from vital NefIgArd study
Calliditas Therapeutics has announced publication of its NefIgArd trial in The Lancet. The phase 3 study concerns the use of Nefecon among adult patients with primary IgA nephropathy (IgAN).
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Calliditas Therapeutics has announced publication of its NefIgArd trial in The Lancet. The phase 3 study concerns the use of Nefecon among adult patients with primary IgA nephropathy (IgAN).